Sunesis Pharmaceuticals (SNSS) was Upgraded by Wells Fargo to ” Outperform”. Earlier the firm had a rating of “Market Perform ” on the company shares. Wells Fargo advised their investors in a research report released on Jul 29, 2016.
On the company’s financial health, Sunesis Pharmaceuticals reported $-0.12 EPS for the quarter, missing the analyst consensus estimate by $ -0.02 based on the information available during the earnings call on Jul 29, 2016. Analyst had a consensus of $-0.10. The company had revenue of $.60 million for the quarter, compared to analysts expectations of $.70 million. The company’s revenue was down -33.3 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $-0.15 EPS.
Sunesis Pharmaceuticals closed down -0.014 points or -2.69% at $0.506 with 2,16,530 shares getting traded on Thursday. Post opening the session at $0.5301, the shares hit an intraday low of $0.505 and an intraday high of $0.54 and the price fluctuated in this range throughout the day.Shares ended Thursday session in Red.
In a different news, on May 27, 2016, Geoffrey M. Parker (director) purchased 9,500 shares at $0.47 per share price. According to the SEC, on Dec 21, 2015, Dayton Misfeldt (director) purchased 1,750,000 shares at $0.84 per share price. On Aug 26, 2015, Daniel N Jr Swisher (CEO) purchased 25,000 shares at $1.01 per share price, according to the Form-4 filing with the securities and exchange commission.
Sunesis Pharmaceuticals Inc. is a biopharmaceutical company. The Company focuses on the development and commercialization of its pipeline of oncology therapeutics for the treatment of solid and hematologic cancers. The Company’s program is QINPREZOTM (vosaroxin) which is its product candidate for the treatment of acute myeloid leukemia (AML). Vosaroxin is an anticancer quinolone derivative (AQD) which is a class of compounds that has not been used previously for the treatment of cancer. Vosaroxin is an AQD which is used for the treatment of cancer. MLN2480 is an oral investigative drug selective for pan-Raf kinase inhibition in patients with relapsed or refractory solid tumors. SNS-062 is a non-covalently binding inhibitor of Bruton’s tyrosine kinase (BTK). PDK1 is a kinase and mediator of PI3K/AKT signaling which is a pathway involved in cell growth differentiation survival and migration.